bladder cancer

Bladder biopsy quality linked to cancer survivalResearch on the quality of bladder biopsy and bladder cancer survival point to problems of suboptimal biopsies and incorrect tumor staging, researchers say.
Urology Product Preview: Oral testosterone agent outperforms gel in hypogonadism studyDrugs and devices in the pipeline from Repros Therapeutics, Bavarian Nordic, NxThera, Solace Therapeutics, Generex Biotechnology, Bioniche, OncoCyte, HistoSonics, and Pacific Edge.
Urology Product Preview: Testosterone agent meets efficacy endpoint in phase III studiesDrugs and devices in the pipeline form Clarus Therapeutics, Nymox Pharmaceutical, Bioniche Life Sciences, Repros Therapeutics, BioLight Life Sciences Investments/Micromedic Technologies, Cubist Pharmaceuticals, Takeda Pharmaceutical, H. Lundbeck A/S, Transplant Genomics, Orion, Bayer, and Roche.
AUA 2014: Studies shine light on new PCa tests, TRT safetyIn our “Best of AUA” report, Urology Times’ editors and writers present the AUA annual meeting’s take-home messages in 15 therapeutic areas.
Best of AUA 2014: Outcomes AnalysisJesse D. Sammon, DO, presents the take home messages on outcomes analysis from the AUA annual meeting in Orlando, FL.
Best of AUA 2014: Bladder CancerWassim Kassouf, MD, CM, presents the take home messages on bladder cancer from the AUA annual meeting in Orlando, FL.
Best of AUA 2014: Basic Science ResearchK.C. Balaji, MD, presents the take home messages on basic science research from the AUA annual meeting in Orlando, FL.
[BLOG] Blessings in disguise Should formularies welcome premium-priced bladder cancer drugs?The management of bladder cancer represents one of the most costly and underestimated challenges in the oncology spectrum. Despite having the 6th highest incidence of any cancer in the United States, high recurrence rates and the need to constantly monitor patients act as the primary drivers for the high expenditures associated with the disease.
Analysis IDs trends in post-cystectomy readmissionsContinent urinary diversion and postoperative complications were found to be independent predictors of hospital readmission following radical cystectomy in an analysis from the University of Wisconsin, Madison.
Urology Product Preview May 2014Drugs and devices in the pipeline from MEI Pharma, Bayer HealthCare, Merck, Pfizer, and Minomic International.